Nocloprost

Nocloprost

SCHEMBL1554645

CCCCC(C)(C)C(O)/C=C/C1C(O)CC(Cl)C1C/C=C\CCCC(=O)O

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 6/20 0.84
TBXA2R P21731 6/20 0.84
PTGER1 P34995 4/20 0.84
PTGFR P43088 4/20 0.84
PTGER2 P43116 4/20 0.60
ALDH1A1 P00352 3/20 0.60
LMNA P02545 3/20 0.60
PTGIR P43119 2/20 0.60
PTGER4 P35408 2/20 0.60
PTGDR Q13258 1/20 0.60
SLCO2A1 Q92959 1/20 0.60
HPGD P15428 2/20 0.55
ABCC4 O15439 1/20 0.55
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
HIF1A Q16665 1/20 0.52
KDM4E B2RXH2 1/20 0.48
HKDC1 Q2TB90 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SAE1 Q9UBE0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nocloprost SCHEMBL436204 1.00 PTGER3 (0.84) PTGER3TBXA2RPTGER1PTGFRPTGER2
Nocloprost SCHEMBL3873408 1.00 PTGER3 (0.84) PTGER3TBXA2RPTGER1PTGFRPTGER2
Nocloprost SCHEMBL9847683 1.00 PTGER3 (0.84) PTGER3TBXA2RPTGER1PTGFRPTGER2
Nocloprost SCHEMBL1554648 1.00 PTGER3 (0.84) PTGER3TBXA2RPTGER1PTGFRPTGER2
Nocloprost SCHEMBL10803435 1.00 PTGER3 (0.84) PTGER3TBXA2RPTGER1PTGFRPTGER2
Nocloprost SCHEMBL9480879 0.95 PTGER3 (0.76) PTGER3TBXA2RPTGER1PTGFRPTGER2
SCHEMBL11484121 0.91 PTGFR (1.00) PTGER3TBXA2RPTGER1PTGFRPTGER2
SCHEMBL3366405 0.91 PTGFR (1.00) PTGER3TBXA2RPTGER1PTGFRPTGER2
SCHEMBL10774699 0.91 PTGFR (0.68) PTGER3TBXA2RPTGER1PTGFRPTGER2
SCHEMBL9481875 0.90 PTGFR (0.68) PTGER3TBXA2RPTGER1PTGFRPTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015109112-A1 COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS GEMMUS PHARMA INC. (US) 2015-07-23 WO claimed
WO-2015109112-A1 COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS GEMMUS PHARMA INC. (US) 2015-07-23 WO disclosed
US-20150196578-A1 COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS GEMMUS PHARMA INC (US) 2015-07-16 US disclosed
EP-2488168-A1 COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS Gemmus Pharma Inc. (US) 2012-08-22 EP disclosed
US-20120190637-A1 COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS GEMMUS PHARMA, INC. (US) 2012-07-26 US disclosed
WO-2011047048-A1 COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS GEMMUS PHARMA, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150196578-A1 COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS PTGER4, TMPRSS4, GPR4 PTGER3 15/4885TBXA2R 80/4885PTGER1 12/4885
US-20120190637-A1 COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS PTGER4, TMPRSS4, GPR4 PTGER3 15/4885TBXA2R 80/4885PTGER1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.